论文部分内容阅读
目的:评价布地奈德与孟鲁司特纳对患儿支原体感染致慢性咳嗽的临床疗效及其血清C-反应蛋白的影响。方法:选取2015年1月—2016年1月间收治的小儿支原体感染致慢性咳嗽患儿84例,按随机数字表法将其分为观察组和对照组,每组42例;对照组患者给予布地奈德治疗,观察组在对照组基础上加用孟鲁司特钠治疗;评价两组患者用药后咳嗽、喘息、肺部啰音改善情况以及治疗前后血清CRP水平。结果:观察组患者治疗后咳嗽、喘息和肺部啰音消失时间均短于对照组(均P<0.05);血清CRP测得值治疗前两组间经比较其差异无统计学意义(P>0.05),治疗后CRP测得值观察组低于对照组(P<0.05)。结论:布地奈德与孟鲁司特钠用于治疗患儿支原体感染致慢性咳嗽的临床疗效较为确切,降低了血清CRP水平,提高了小儿支原体感染致慢性咳嗽疗效。
Objective: To evaluate the clinical efficacy of budesonide and montelukastine in the treatment of chronic cough caused by mycoplasma infection in children and its effect on serum C-reactive protein. Methods: Eighty-four children with chronic cough caused by mycoplasma chlamydialis infection were selected from January 2015 to January 2016, and divided into observation group and control group according to random number table method, with 42 cases in each group. Patients in control group Budesonide treatment, the observation group plus montelukast sodium on the basis of the control group; evaluation of two groups of patients cough, wheezing, pulmonary rales improved after treatment and serum CRP levels before and after treatment. Results: The cough, wheezing and pulmonary rales disappeared in the observation group were shorter than those in the control group (all P <0.05). There was no significant difference between the two groups before and after treatment (P> 0.05). After treatment, the observed value of CRP in observation group was lower than that in control group (P <0.05). Conclusion: The clinical efficacy of budesonide and montelukast sodium in the treatment of chronic cough caused by mycoplasma infection in children is relatively accurate, which reduces the level of serum CRP and improves the curative effect of chronic cough caused by mycoplasma infection in children.